Exelixis Inc at Needham Healthcare Conference Transcript
I think most of you know me, but I'm Chad Messer, Senior Biotech Analyst, here at Needham and with me today is Chris Senner, the Chief Financial Officer; and Andrew Peters, Vice President of Strategy from Exelixis. And I will kick it off so maybe one or both of you if you'd like to make some opening remarks.
Yes. Well, thank you, thanks for the invitation for the -- to be at the meeting here and the opportunity to present at the fireside chat. In the course of the discussion today, we'll be making forward-looking statements. So I'll refer you to the SEC filings that we do from time to time.
So I guess from an Exelixis perspective, we're a commercial-stage oncology company, profitable, cash flow generating. We don't have any debt. We have $850 million of cash and no debt. And we have an asset in cabozantinib, which is currently approved in frontline RCC, second line later RCC, second line later HCC. We also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
